Medpace Holdings, Inc.(MEDP) Stock Research - Grey Stern Research

Medpace Holdings, Inc. (MEDP) Stock Analysis

$381.47 (0.25%)

MEDP Financial Performance


Use the table below to view Medpace Holdings, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $380.50 -
52 Week Low $227.21 -
52 Week High $459.77 -
Market Cap $11.8 Billion 7/12
Gross Margin 30% 8/12
Profit Margin 20% 2/12
EBITDA margin 22% 6/12
Q1 - 2024 Revenue $511.0 Million 9/12
Q1 - 2024 Earnings $102.6 Million 6/12
Q1 - 2024 Free Cash Flow $147.2 Million 6/12
Trailing 4 Quarters Revenue $2.0 Billion 9/12
Trailing 4 Quarters Earnings $312.5 Million 9/12
Quarterly Earnings Growth 41% 3/12
Annual Earnings Growth 12% 4/12
Quarterly Revenue Growth 18% 2/12
Annual Revenue Growth 21% 2/12
Cash On Hand $407.0 Million 3/12
Short Term Debt $272.3 Million 5/12
Long Term Debt $136.2 Million 11/12

Medpace Holdings, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Medpace Holdings, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 37.72 7/12
PS 6.01 5/12
PB 17.56 2/12
PC 28.97 9/12
Liabilities to Equity 1.67 3/12
ROA 0.17 3/12
ROE 0.47 3/12
Current Ratio 1.60 9/12
Quick Ratio 0.36 3/12
Long Term Debt to Equity 0.20 10/12
Debt to Equity 0.20 10/12
Burn Rate -14.00 11/12
Cash to Cap 0.03 4/12
CCR 1.43 4/12
EV to EBITDA 103.71 4/12
EV to Revenue 5.87 5/12

Company Details

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

CEO: DR. August Troendle

Website: https://www.medpace.com

Address: 5375 Medpace Way Cincinnati, OHIO

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

Medpace Holdings, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Medpace Holdings, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Syneos Health, Inc. SYNH $4.5 Billion
Qiagen N.V. QGEN $9.7 Billion
Laboratory Corporation of America Holdings LH $17.8 Billion
IDEXX Laboratories, Inc. IDXX $38.8 Billion
IQVIA Holdings Inc. IQV $43.7 Billion
Waters Corporation WAT $18.9 Billion
Charles River Laboratories International, Inc. CRL $12.0 Billion
Mettler-Toledo International Inc. MTD $31.0 Billion
ICON Public Limited Company ICLR $26.7 Billion
Neogen Corporation NEOG $3.8 Billion
Twist Bioscience Corporation TWST $3.4 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
MEDP Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 511.0 Million $102.6 Million
Q4 2023 $ 498.4 Million $78.3 Million
Q3 2023 $ 492.5 Million $70.6 Million
Q2 2023 $ 460.9 Million $61.1 Million
Q1 2023 $ 434.1 Million $72.9 Million
Q4 2022 $ 394.1 Million $68.7 Million
Q3 2022 $ 383.7 Million $66.0 Million
Q2 2022 $ 351.2 Million $49.4 Million

View All

MEDP Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $407.0 Million $1.8 Billion $136.2 Million $671.5 Million
Q4 2023 $245.4 Million $1.7 Billion $142.1 Million $559.0 Million
Q3 2023 $95.2 Million $1.5 Billion $143.0 Million $470.9 Million
Q2 2023 $39.1 Million $1.4 Billion $194.4 Million $391.1 Million
Q1 2023 $46.9 Million $1.4 Billion $257.7 Million $347.3 Million
Q4 2022 $28.3 Million $1.4 Billion $188.9 Million $386.4 Million
Q3 2022 $31.0 Million $1.3 Billion $278.9 Million $349.9 Million
Q2 2022 $42.6 Million $1.3 Billion $384.7 Million $283.3 Million

View All

MEDP Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $147.2 Million -$5.5 Million $161.6 Million
Q4 2023 $4.6 Million $0 $4.6 Million
Q3 2023 $105.7 Million -$8.7 Million $56.1 Million
Q2 2023 $74.1 Million -$8.4 Million -$7.8 Million
Q1 2023 $70.6 Million -$9.5 Million $18.7 Million
Q4 2022 $127.4 Million -$9.2 Million -$2.7 Million
Q3 2022 $101.3 Million -$7.2 Million -$11.5 Million
Q2 2022 $85.4 Million -$11.2 Million -$40.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions